5-(4-methoxyphenyl)-2-methylfuran-3-carbaldehyde | 1150223-61-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-(4-methoxyphenyl)-2-methylfuran-3-carbaldehyde
• 英文别名: 5-(4-Methoxyphenyl)-2-methylfuran-3-carbaldehyde
• CAS: 1150223-61-2
• 化学式: C₁₃H₁₂O₃
• 分子量: 216.236
• InChiKey: WJCTYGGJTPUHRI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(4-methoxyphenyl)-2-methylfuran-3-carbaldehyde 、 环己基溴化镁 在 盐酸 、 水 作用下， 以 四氢呋喃 为溶剂， 以95%的产率得到cyclohexyl[5-(4-methoxyphenyl)-2-methylfuran-3-yl]methanol
  参考文献：
  名称：

  HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST

  摘要：

  公开号：

  EP2210876B1
• 作为产物：
  描述：

  5-bromo-2-methylfuran-3-carbaldehyde 、 4-甲氧基苯硼酸 在 四(三苯基膦)钯 sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 以91%的产率得到5-(4-methoxyphenyl)-2-methylfuran-3-carbaldehyde
  参考文献：
  名称：

  HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST

  摘要：

  公开号：

  EP2210876B1

文献信息

• Heterocyclic compound
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US08309580B2

  公开（公告）日：2012-11-13

  The present invention provides a heterocyclic compound represented by the following formula (I), which has a glucagon antagonistic action and is useful for the prophylaxis or treatment of diabetes and the like, a compound represented by wherein ring A is an optionally substituted benzene ring and the like; Y is a nitrogen atom and the like; X is —O— and the like; R4 is a hydrogen atom and the like; R5 and R6 are each independently a hydrogen atom and the like; R1 is an optionally substituted hydrocarbon group and the like; R2 is a hydrogen atom and the like; and R3 is —(CH2)3—COOH and the like, or a salt thereof.

  本发明提供了一种杂环化合物，其由以下式子（I）表示，具有葡萄糖升高素拮抗作用，用于预防或治疗糖尿病等疾病，其中化合物由以下表示： 其中环A是可选取代的苯环等；Y是氮原子等；X是—O—等；R4是氢原子等；R5和R6各自独立地是氢原子等；R1是可选取代的烃基等；R2是氢原子等；R3是—（CH2）3—COOH等，或其盐。
• HETEROCYCLIC COMPOUND
  申请人：Banno Yoshihiro

  公开号：US20100256156A1

  公开（公告）日：2010-10-07

  The present invention provides a heterocyclic compound represented by the following formula (I), which has a glucagon antagonistic action and is useful for the prophylaxis or treatment of diabetes and the like, a compound represented by wherein ring A is an optionally substituted benzene ring and the like; Y is a nitrogen atom and the like; X is —O— and the like; R 4 is a hydrogen atom and the like; R 5 and R 6 are each independently a hydrogen atom and the like; R 1 is an optionally substituted hydrocarbon group and the like; R 2 is a hydrogen atom and the like; and R 3 is —(CH 2 ) 3 —COOH and the like, or a salt thereof.

  本发明提供了一种由以下式（I）表示的杂环化合物，该化合物具有葡萄糖高升素拮抗作用，并可用于预防或治疗糖尿病等疾病，其中，式中环A为可选取代苯环等；Y为氮原子等；X为—O—等；R4为氢原子等；R5和R6各自独立地为氢原子等；R1为可选取代的碳氢基团等；R2为氢原子等；R3为—（CH2）3—COOH等，或其盐。
• NOVEL ESTER COMPOUND AND PIN1 INHIBITOR, INFLAMMATORY DISEASE THERAPEUTIC, AND COLON CANCER THERAPEUTIC IN WHICH SAID ESTER COMPOUND IS USED
  申请人：Hiroshima University

  公开号：EP3549930A1

  公开（公告）日：2019-10-09

  An object of the present invention is to develop a therapeutic agent for an inflammatory disease such as an inflammatory bowel disease or NASH, which therapeutic agent shows less side effects and high effectiveness. The present invention provides a compound represented by Formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic agent or a prophylactic agent for an inflammatory disease, and a therapeutic agent or a prophylactic agent for colon cancer, containing the compound.

  本发明的目的是开发一种用于炎症性疾病（如炎症性肠病或 NASH）的治疗剂，该治疗剂副作用小且疗效显著。本发明提供了一种由式（I）代表的化合物或其盐；以及一种含有该化合物的 Pin1 抑制剂、一种药物组合物、一种炎症性疾病的治疗剂或预防剂，以及一种结肠癌的治疗剂或预防剂。
• US7569602B2
  申请人：——

  公开号：US7569602B2

  公开（公告）日：2009-08-04
• US8309580B2
  申请人：——

  公开号：US8309580B2

  公开（公告）日：2012-11-13